......SMARTEST Trial......
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Himalaya Early Access Program
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE3
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study
- Status
- UNKNOWN
- Phase
- PHASE2
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
Chemo-free BRCA-targeted Neoadjuvant Strategy
- Status
- WITHDRAWN
- Phase
- PHASE2
Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2